ARGX and 0QW0 Related Headlines

Go Back

Aug 17, 2026 06:00AM Zai Lab and argenx report Phase 3 trial win for myositis drug
Aug 17, 2026 06:00AM Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Aug 6, 2026 07:49AM argenx launches $77-per-share tender offer for Forte Biosciences
Aug 6, 2026 07:48AM argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
Jul 16, 2026 01:00AM argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
Jun 23, 2026 01:00AM argenx to Host Autoimmune Myositis R&D Webinar
May 28, 2026 01:00AM argenx to Host Myositis R&D Webinar on June 23, 2026
May 27, 2026 01:00AM argenx to Present at Upcoming Investor Conferences
May 18, 2026 08:34AM The Biology Came First.
May 7, 2026 01:00AM argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026 04:02PM argenx names Karen Massey as CEO, Van Hauwermeiren becomes chairman
May 6, 2026 04:01PM argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

ARGX and 0QW0 Related Press Releases

Go Back

Aug 17, 2026 06:00AM Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Aug 6, 2026 07:48AM argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
Jul 16, 2026 01:00AM argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
Jun 23, 2026 01:00AM argenx to Host Autoimmune Myositis R&D Webinar
May 28, 2026 01:00AM argenx to Host Myositis R&D Webinar on June 23, 2026
May 27, 2026 01:00AM argenx to Present at Upcoming Investor Conferences
May 18, 2026 08:34AM The Biology Came First.
May 7, 2026 01:00AM argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026 04:01PM argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

ARGX and 0QW0 Related SEC Filings

Go Back

Aug 27, 2026 04:20PM Form 6-K ARGENX SE For: Aug 27
Aug 17, 2026 08:54AM Form 6-K ARGENX SE For: Aug 17
Aug 14, 2026 10:39AM Form SCHEDULE 13G/A ARGENX SE Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Aug 3, 2026 04:13PM Form 6-K ARGENX SE For: Aug 03
Jul 27, 2026 06:03AM Form 6-K ARGENX SE For: Jul 27
Jul 23, 2026 08:22AM Form 6-K ARGENX SE For: Jun 30
Jun 23, 2026 06:23AM Form 6-K ARGENX SE For: Jun 23
Jun 3, 2026 07:16AM Form 6-K ARGENX SE For: Jun 03
May 11, 2026 06:03AM Form 6-K ARGENX SE For: May 08
May 7, 2026 08:46AM Form 6-K ARGENX SE For: Mar 31
May 6, 2026 04:29PM Form 6-K ARGENX SE For: May 06
May 6, 2026 11:01AM Form SCHEDULE 13G/A ARGENX SE Filed by: FMR LLC
Apr 20, 2026 06:02AM Form 6-K ARGENX SE For: Apr 20
Mar 20, 2026 04:24PM Form 6-K ARGENX SE For: Mar 20
Mar 19, 2026 06:13AM Form 20-F ARGENX SE For: Dec 31
Mar 19, 2026 06:07AM Form 6-K ARGENX SE For: Dec 31
Mar 6, 2026 06:15AM Form 6-K ARGENX SE For: Mar 06
Feb 26, 2026 08:37AM Form 6-K ARGENX SE For: Dec 31
Feb 26, 2026 06:20AM Form 6-K ARGENX SE For: Feb 26
Jan 13, 2026 06:05AM Form 6-K ARGENX SE For: Jan 13
Jan 12, 2026 04:06PM Form 6-K ARGENX SE For: Jan 12
Jan 5, 2026 07:26AM Form 6-K ARGENX SE For: Jan 05
Dec 17, 2025 04:11PM Form S-8 ARGENX SE
Dec 15, 2025 06:15AM Form 6-K ARGENX SE For: Dec 15
Nov 18, 2025 05:02PM Form 6-K ARGENX SE For: Nov 18
Nov 14, 2025 12:20PM Form SCHEDULE 13G/A ARGENX SE Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Oct 30, 2025 08:04AM Form 6-K ARGENX SE For: Sep 30
Oct 29, 2025 11:11AM Form 6-K ARGENX SE For: Oct 29
Oct 15, 2025 06:09AM Form 6-K ARGENX SE For: Oct 15
Oct 3, 2025 04:32PM Form 6-K ARGENX SE For: Oct 03